MIRXES-B (02629) announced that it has recently entered into a memorandum of understanding (MOU) with XTALPI Holdings Limited (XTALPI). Under the agreement, the two parties will combine MIRXES-B's core strengths in genomics technology and its extensive Asian-centric disease database with XTALPI's leading AI and robotics-driven drug discovery and research platform. The collaboration aims to establish an AI-powered, innovative "diagnosis-treatment integration" research and industrialization platform focused on early detection and intervention for cancers prevalent in Asia, particularly gastrointestinal cancers.

The MOU, effective upon signing, will remain valid for two years. This partnership aligns with both companies' long-term goals of advancing early detection and intervention to promote healthier lives. It also marks MIRXES-B's strategic expansion from early detection into early intervention and precision medicine.

By leveraging their complementary strengths—MIRXES-B's high-quality cancer biomarker data, diagnostic resources, and operational advantages in the Asia-Pacific region, alongside XTALPI's AI-driven biopharmaceutical R&D platform, drug development expertise, and big data capabilities—the collaboration seeks to jointly develop and industrialize AI-powered, innovative early diagnosis and treatment solutions for high-incidence cancers in Asia, particularly gastrointestinal cancers.